Sang-Woo Park
Directeur Général chez NKMAX CO., LTD.
Fortune : 671 775 $ au 31/05/2024
Profil
Mr. Sang-Woo Park is a Chairman & Chief Executive Officer at Nkmax Japan, Inc., a Chairman & Chief Executive Officer at Atgen Japan, a Chairman & Chief Executive Officer at Nkmax H&D Co. Ltd., a Chairman & Chief Executive Officer at coAsia Biotech Corp., a Chief Executive Officer at Atgen H&D, a Chairman & Chief Executive Officer at ATGen America, Inc., a Chairman & Chief Executive Officer at ATGen Canada, Inc., a Chairman & Chief Executive Officer at NKMAX Co., Ltd.
(South korea) and a Chairman & Chief Executive Officer at NKMAX Co., Ltd.
He is on the Board of Directors at NKGen Biotech, Inc. Mr. Park was previously employed as a Chief Executive Officer & Director by J way Co., Ltd.
He also served on the board at NKGen Biotech, Inc. /US/.
He received his undergraduate degree from Korea University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
1,60% | 29/04/2024 | 397 378 ( 1,60% ) | 663 621 $ | 31/05/2024 |
NKMAX CO., LTD.
0,01% | 26/01/2024 | 5 418 ( 0,01% ) | 8 154 $ | 31/03/2024 |
Postes actifs de Sang-Woo Park
| Sociétés | Poste | Début |
|---|---|---|
| NKMAX CO., LTD. | Directeur Général | 31/03/2023 |
| ATGen America, Inc. | Directeur Général | 01/02/2014 |
| ATGen Canada, Inc. | Directeur Général | 01/09/2013 |
Atgen H&D
 Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Directeur Général | 01/01/2016 |
NKMAX Co., Ltd.
 NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Directeur Général | 01/01/2002 |
| Nkmax H&D Co. Ltd. | Directeur Général | 01/06/2016 |
coAsia Biotech Corp.
 coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Directeur Général | 01/04/2016 |
| Atgen Japan | Directeur Général | 01/09/2017 |
| Nkmax Japan, Inc. | Directeur Général | 01/11/2017 |
Anciens postes connus de Sang-Woo Park
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░ ░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
Formation de Sang-Woo Park
| Korea University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| J WAY CO., LTD. | Consumer Services |
| NKMAX CO., LTD. | Health Technology |
| Entreprise privées | 9 |
|---|---|
| ATGen America, Inc. | |
| ATGen Canada, Inc. | |
Atgen H&D
Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Health Technology |
NKMAX Co., Ltd.
NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Health Technology |
| Nkmax H&D Co. Ltd. | |
coAsia Biotech Corp.
coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Health Technology |
| Atgen Japan | |
NKGen Biotech, Inc.
 NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Health Technology |
| Nkmax Japan, Inc. |
